JAM
HRTX icon

JW Asset Management’s Heron Therapeutics HRTX Stock Holding History

JW Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.6M Hold
3,751,073
– – 0.5% 14
2026
Q1 		$3M Buy
3,751,073
+80,000
+2% +$92.7K 1.23% 11
2025
Q4 		$4.77M Buy
3,671,073
+378,440
+11% +$467K 1.55% 10
2025
Q3 		$4.15M Buy
3,292,633
+954,890
+41% +$1.51M 1.99% 8
2025
Q2 		$4.84M Hold
2,337,743
– – 2.39% 7
2025
Q1 		$5.14M Buy
2,337,743
+45,325
+2% +$88K 2.91% 5
2024
Q4 		$3.51M Hold
2,292,418
– – 1.67% 7
2024
Q3 		$4.56M Hold
2,292,418
– – 2.06% 7
2024
Q2 		$8.02M Hold
2,292,418
– – 3.31% 6
2024
Q1 		$6.35M Hold
2,292,418
– – 2.32% 10
2023
Q4 		$3.9M Sell
2,292,418
-115,000
-5% -$127K 2.22% 9
2023
Q3 		$2.48M Buy
2,407,418
+200,000
+9% +$285K 1.07% 9
2023
Q2 		$2.56M Buy
+2,207,418
New +$3.94M 0.93% 7
2015
Q1 		– Sell
-3,275
Closed -$33K – 50
2014
Q4 		$33K Buy
+3,275
New +$26.7K 0.02% 53

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JW Asset Management's HRTX Position: Q2 2026 in Review

JW Asset Management held its Heron Therapeutics (HRTX) position steady in Q2 2026 at 3,751,073 shares worth $1.6M. The position accounts for 0.5% of the portfolio, ranked #14.

JW Asset Management first reported a position in HRTX in Q4 2014 and has held it in 14 quarters since. The position peaked at $8.02M in Q2 2024. 163 funds tracked by Wall St. Rank hold HRTX as of Q2 2026.

  • JW Asset Management held 3,751,073 shares of Heron Therapeutics worth $1.6M as of Q2 2026.
  • JW Asset Management left its Heron Therapeutics share count unchanged in Q2 2026.
  • Heron Therapeutics made up 0.5% of JW Asset Management's portfolio in Q2 2026, its #14 holding.
  • JW Asset Management first reported a position in Heron Therapeutics in Q4 2014 and has held it in 14 quarters since.
  • JW Asset Management's Heron Therapeutics position peaked at $8.02M in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2026.

Based on JW Asset Management's 13F filing for Q2 2026, filed 7 Aug 2026.